Author(s):
Maya Y. Gaikwad, Neha Kharat
Email(s):
gaikwadmau012@gmail.com
DOI:
10.52711/2231-5713.2025.00010 
Address:
Maya Y. Gaikwad1*, Neha Kharat2
1Assistant Professor, SMBT College of Pharmacy, Dhamangaon, Nashik, Maharashtra.
2Student, SMBT College of Pharmacy, Dhamangaon, Nashik, Maharashtra.
*Corresponding Author
Published In:
Volume - 15,
Issue - 1,
Year - 2025
ABSTRACT:
Immunotherapy represents a significant breakthrough in the battle against cancer, offering promising outcomes and potential for improved survival rates and quality of life for patients. While therapies such as immune checkpoint inhibitors, CAR-T cell therapy, Tumor-infiltratings Lymphocytes, monoclonal antibodies, cancer vaccines, and Adoptive Cell Transfer have shown effectiveness, they also come with limitations and challenges. Continued research is essential to address these obstacles and enhance the efficacy and safety of immunotherapy across a wider range of cancer types. With ongoing advancements and refinement, immunotherapy holds the potential to achieve long-term remission and even complete recovery for some patients, marking a transformative milestone in cancer treatment.
Cite this article:
Maya Y. Gaikwad, Neha Kharat. Immunotherapy in Cancer its Recent Advances and Challenges. Asian Journal of Pharmacy and Technology. 2025; 15(1):57-5. doi: 10.52711/2231-5713.2025.00010
Cite(Electronic):
Maya Y. Gaikwad, Neha Kharat. Immunotherapy in Cancer its Recent Advances and Challenges. Asian Journal of Pharmacy and Technology. 2025; 15(1):57-5. doi: 10.52711/2231-5713.2025.00010 Available on: https://ajptonline.com/AbstractView.aspx?PID=2025-15-1-10
REFERENCES:
1. Ling SP, Ming LC, Dhaliwal JS, Gupta M, Ardianto C, Goh KW, et al. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. Vol. 14, Cancers. MDPI; 2022.
2. Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. Vol. BBA Clinical. Elsevier; 2015. p. 280–8.
3. Wang RF. A special issue on cancer immunotherapy. Vol. 27, Cell Research. Nature Publishing Group; 2017. p. 1–2.
4. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Vol. 29, Current Oncology. MDPI; 2022. p. 3044–60.
5. Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Vol. 21, Nature Reviews Cancer. Nature Research; 2021. p. 298–312.
6. Hamaï A, Benlalam H, Meslin F, Hasmim M, Carré T, Akalay I, et al. Immune surveillance of human cancer: If the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Vol. 75, Tissue Antigens. 2010. p. 1–8.
7. Alturki NA. Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment. Vol. 12, Journal of Clinical Medicine. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
8. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Vol. 11, Blood Cancer Journal. Springer Nature; 2021.
9. Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, et al. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. Vol. 2020, Journal of Immunology Research. Hindawi Limited; 2020.
10. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017 Mar 21;5(1).
11. Mclaughlin P, Grillo-L6pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. Vol. 16, J Clin Oncol. 1998.
12. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clinical Cancer Research. 2009 Mar 1;15(5):1585–92.
13. Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Vol. 9, Antibodies. MDPI; 2020. p. 1–20.
14. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Vol. 62, International Immunopharmacology. Elsevier B.V.; 2018. p. 29–39.
15. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clinical Cancer Research. 2008 May 15;14(10):3044–51.
16. Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Vol. 3, Nature Cancer. Nature Research; 2022. p. 911–26.
17. Titov A, Zmievskaya E, Ganeeva I, Valiullina A, Petukhov A, Rakhmatullina A, et al. Adoptive immunotherapy beyond CAR T-cells. Vol. 13, Cancers. MDPI AG; 2021. p. 1–23.
18. Sharkey RM, Goldenberg DM. Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. CA Cancer J Clin. 2006 Jul 1;56(4):226–43.
19. Zhao D, Zhu D, Cai F, Jiang M, Liu X, Li T, et al. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies. Vol. 22, Technology in Cancer Research and Treatment. SAGE Publications Inc.; 2023.
20. Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, et al. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Vol. 14, Cancers. MDPI; 2022.
21. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Vol. 94, American Journal of Hematology. Wiley-Liss Inc.; 2019. p. S3–9.
22. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Vol. 81, European Journal of Cancer. Elsevier Ltd; 2017. p. 116–29.
23. Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. new approaches and procedures for cancer treatment: Current perspectives. Vol. 9, SAGE Open Medicine. SAGE Publications Ltd; 2021.
24. Dhar R, Seethy A, Singh S, Pethusamy K, Srivastava T, Talukdar J, et al. Cancer immunotherapy: Recent advances and challenges. Vol. 17, Journal of Cancer Research and Therapeutics. Wolters Kluwer Medknow Publications; 2021. p. 834–44.
25. Baronzio Gianfranco G, Parmar Gurdev, Ballerini Marco, Kiselevsky Mikhail, Cassuti Valter, Irina Zh Shubina, et al. Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther. 2013 Jun;39.
26. Yang L, Ning Q, Tang SS. Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. Vol. 2022, Journal of Immunology Research. Hindawi Limited; 2022.
27. Baronzio Gianfranco G, Parmar Gurdev, Ballerini Marco, Kiselevsky Mikhail, Cassuti Valter, Irina Zh Shubina, et al. Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther. 2013 Jun;39.
28. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon S V., Papneja N, Miller WH. A review of cancer immunotherapy: From the past, to the present, to the future. Current Oncology. 2020;27(S2):87–97.
29. Suda K. Recent advances in cancer immunotherapy. Biomolecules. 2021 Feb 1;11(2):1–3.
30. Holthof LC, Mutis T. Challenges for immunotherapy in multiple myeloma: Bone marrow microenvironment-mediated immune suppression and immune resistance. Vol. 12, Cancers. MDPI AG; 2020.